Study guide

5.5 Physical Assessment and Point-of-Care Testing

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

5.5 Physical Assessment and Point-of-Care Testing

Key Takeaways Explain This Topic AI

Point-of-care testing supports but does not replace clinical assessment, and every device requires quality control, operator training, and a documented result.

A capillary point-of-care international normalized ratio is not interchangeable with a laboratory venous value and becomes less reliable at high values and in antiphospholipid syndrome.

Orthostatic hypotension is defined as a fall of at least 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing.

Point-of-care glycated hemoglobin devices vary in accuracy and are unreliable in hemoglobinopathies, recent transfusion, pregnancy, and conditions altering red cell turnover.

Pulse oximetry measures oxygen saturation rather than ventilation, and it is falsely normal or high in carbon monoxide poisoning.

Last updated: August 2026

5.5 Physical Assessment and Point-of-Care Testing

Exam Focus: The blueprint pairs "clinical biochemistry and diagnostic testing (including point-of-care testing)" in a single subcategory, and the syllabus separately requires "completion of a comprehensive patient assessment (including relevant physical assessments)". Items usually turn on a technique error or a device limitation.

Vital Signs and Their Drug Therapy Meaning

Sign Normal adult range Common drug-related interpretation

Blood pressure Under 120/80 mmHg optimal Efficacy of antihypertensives; orthostatic drop from alpha-blockers, diuretics, nitrates

Heart rate 60 to 100 beats per minute Bradycardia from beta-blockers, non-dihydropyridine calcium channel blockers, digoxin; tachycardia from salbutamol, decongestants, withdrawal

Respiratory rate 12 to 20 breaths per minute Depression with opioids and sedatives; elevation in metabolic acidosis

Temperature About 36.5 to 37.5 degrees Celsius Infection; drug fever; neuroleptic malignant syndrome; serotonin syndrome

Oxygen saturation 95 to 100 percent on room air Target 88 to 92 percent in those at risk of carbon dioxide retention

Orthostatic vital signs are measured supine after five minutes, then standing at one and three minutes. A fall of 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing , or a rise in heart rate above about 20 beats per minute, defines orthostatic hypotension. In an older adult presenting with falls or dizziness, this single measurement frequently identifies the responsible drug.

Pain is assessed as a vital sign using a numeric or visual analogue scale, with attention to onset, provocation, quality, radiation, severity, and timing.

Focused Physical Assessment Within Pharmacist Scope

Pharmacists in Canada perform focused assessment relevant to medication decisions rather than diagnostic examination.

Weight, height, and body mass index , plus waist circumference, are needed for dosing, for renal function estimation, and for cardiometabolic risk.

Peripheral edema is graded by pitting depth and recovery time and points to calcium channel blockers, thiazolidinediones, gabapentinoids, or worsening heart failure.

Injection and infusion sites are inspected for lipohypertrophy, erythema, and induration.

Skin assessment covers rash morphology and distribution, and the identification of severe cutaneous reactions.

Inhaler and device technique observation is a physical assessment in its own right and is more informative than any patient self-report.

Cognitive and functional screening where a validated tool is used, alongside falls risk assessment.

Refer promptly rather than continuing to assess where there is chest pain, focal neurological deficit, respiratory distress, signs of sepsis, or a rapidly evolving rash with mucosal involvement.

Point-of-Care Testing: Principles

Point-of-care testing is diagnostic testing performed near the patient with a rapid result. In pharmacy it supports screening, monitoring, and treatment decisions, and provincial authority for specific tests varies.

Every point-of-care program requires:

Training and demonstrated competence for every operator.

Quality control at the intervals the manufacturer specifies and after every new reagent lot, with documented results and defined action when control values fall outside range.

Documentation of the result in the patient record, with the device and lot identified.

A defined action pathway — what result triggers what response, including referral.

Infection control and sharps management , since almost all involve capillary blood.

Informed consent , explaining what the test does and does not establish.

The unifying limitation is that a point-of-care result is not interchangeable with a laboratory result . Devices use different methods and calibrations, and a decision at a clinical threshold should be confirmed by laboratory testing.

Common Tests and Their Traps

Test Use Key limitations

Capillary blood glucose Diabetes monitoring, hypoglycemia Falsely high with sugar residue on the skin; affected by hematocrit, temperature, and altitude

Glycated hemoglobin (A1C) Glycemic control over roughly 3 months Unreliable in hemoglobinopathies, recent transfusion, hemolysis, iron deficiency, pregnancy, and advanced kidney disease; device accuracy varies

Lipid panel Cardiovascular risk screening Non-fasting acceptable for most screening; triglycerides are most affected by recent food

International normalized ratio (INR) Warfarin monitoring Capillary and venous values are not interchangeable; less reliable at high INR and unreliable in antiphospholipid syndrome

Rapid strep antigen Pharyngitis triage Good specificity but imperfect sensitivity; a negative in a high-probability child may need culture

Influenza and COVID-19 antigen Respiratory triage Sensitivity depends on timing, symptom stage, and swab technique; a negative result does not exclude infection

Pulse oximetry Oxygenation Measures saturation, not ventilation or carbon dioxide; unreliable with poor perfusion, nail polish, and motion; falsely reassuring in carbon monoxide poisoning ; accuracy can be reduced at higher skin pigmentation

Spirometry Airflow obstruction Highly effort-dependent; requires trained coaching and acceptable, repeatable manoeuvres

Carbon monoxide poisoning deserves emphasis. Carboxyhemoglobin absorbs light similarly to oxyhemoglobin at the wavelengths a standard pulse oximeter uses, so the displayed saturation can be normal while the patient is severely hypoxic. Diagnosis requires co-oximetry, and the treatment is high-flow oxygen.

Interpreting Any Test Result

Four questions apply to every point-of-care and laboratory result:

Is the result plausible given the patient in front of you? A result that contradicts the clinical picture is repeated, not acted on.

Was the pre-analytical process correct? Technique, sample quality, timing relative to doses, and device maintenance produce more errors than the analytic step.

What is the pre-test probability? In a low-prevalence population, even a specific test produces a substantial proportion of false positives, which is why screening asymptomatic people rarely helps.

What action will follow? A test that will not change management should not be performed.

Communicate results in plain language, explain what a negative result does and does not exclude, document the result and the action taken, and share it with the patient's other providers where it affects their care.